#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Type IIa hyperlipidaemia Lymphoma Thrombocytopenia Follicular lymphoma Acute myeloid leukaemia Epileptic encephalopathy Arrhythmia Necrotising myositis Congenital leptin deficiency Oesophageal squamous cell carcinoma stage III Scedosporium infection Adult T-cell lymphoma/leukaemia refractory Duchenne muscular dystrophy gene carrier Prader-Willi syndrome Brain stem glioma More trials…

    Learn about Rare Diseases

    Primary biliary cholangitis Lymphangioma – Treatment Congenital generalised lipodystrophy – Basic Information Pemphigus – Treatment Synovial sarcoma – Treatment Immunodeficiency congenital – Diagnostics Haemophilia B with anti factor IX – Basic Information Amyotrophic lateral sclerosis – Treatment Marginal zone lymphoma refractory – Trials in Disease Rett syndrome – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    BENZYLPENICILLIN POTASSIUM SOFOSBUVIR Buspirone Hydrochloride Sertraline AB521 Kpl-404 Avb-101 Lanifibranor Dacarbazine Nimotuzumab Abt-494 Disitamab Vedotin Ociperlimab Tovinontrine Darunavir Mva-209-Fsp-B2 Bendamustine Hydrochloride TRIGLYCERIDES MEDIUM CHAIN Aflibercept Octocog Alfa More therapies…

    Learn about Your Condition

    Acne Cushing's syndrome Psychotic disorder Shprintzen-Goldberg syndrome Dermatitis atopic Dystonia Senile dementia Appendicitis Malignant peritoneal neoplasm Large cell lung cancer Bronchostenosis Ocular melanoma Generalised anxiety disorder Hepatoblastoma Epstein-Barr virus infection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Type 2 diabetes mellitus

  • Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

    Recruiting

    3 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    • Obesity
    • Overweight
    Investigated Drugs:
    • Semaglutide
    Bulgaria Croatia Germany Hungary Poland Portugal +1

  • A Study of Zenagamtide in Adults With Overweight or Obesity and Type 2 Diabetes

    Recruiting

    3 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    • Obesity
    • Overweight
    Croatia Hungary Italy Romania Slovakia

  • A study to evaluate the effect of CX11 trometamol monohydrate in patients with type 2 diabetes

    Recruiting

    2 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Poland

  • A study to evaluate the effectiveness of NNC0662-0419 and semaglutide in people with type 2 diabetes

    Recruiting

    2 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Semaglutide
    Croatia Hungary Poland Portugal Slovakia Spain

  • Study of LY3457263 compared to placebo in adults with type 2 diabetes who are taking semaglutide or tirzepatide but have not reached their blood sugar goals

    Recruiting

    2 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Tirzepatide
    Germany Poland

  • Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

    Recruiting

    3 1 1
    Investigated Diseases:
    • Cardiovascular disorder
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Bi 690517
    • Empagliflozin
    Austria Belgium Bulgaria Croatia Czechia Denmark +17
1 2 3 … 13
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!